← Back to Search

Monoclonal Antibodies

Nivolumab + Plinabulin for Non-Small Cell Lung Cancer

Phase 1
Waitlist Available
Led By Lyudmilla Bazhenova, MD
Research Sponsored by Lyudmila Bazhenova, M.D.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing whether the investigational drug plinabulin, in combination with the standard treatment nivolumab, can help to shrink tumors in people with metastatic squamous non-small cell lung cancer that has progressed after treatment with platinum-based chemotherapy.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Frequency and severity of treatment-related adverse events as assessed by CTCAE v4.
Maximum tolerated dose (MTD)
Secondary outcome measures
Disease control rate (DCR)
Objective response rate (ORR)
Overall survival (OS)
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Nivolumab + PlinabulinExperimental Treatment1 Intervention
Nivolumab 240mg IV, day 1 and 15 until disease progression Plinabulin 3.5mg/m2, 20mg/m2, 30 mg/m2 or 40mg/m2 IV, day 1,8 and 15 until disease progression

Find a Location

Who is running the clinical trial?

Lyudmila Bazhenova, M.D.Lead Sponsor
1 Previous Clinical Trials
7 Total Patients Enrolled
BeyondSpring Pharmaceuticals Inc.Industry Sponsor
8 Previous Clinical Trials
1,158 Total Patients Enrolled
Lyudmilla Bazhenova, MDPrincipal InvestigatorUniversity of California, San Diego

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Lyudmila Bazhenova, M.D. 2016. "Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02812667.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top